Sanofi SA (EPA: SAN)‘s stock had its “buy” rating reiterated by equities research analysts at Bryan Garnier & Cie in a research note issued to investors on Wednesday. They currently have a $102.56 (€80) price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at Liberum Capital Ltd reiterated an “underweight” rating on shares of Sanofi SA in a research note to investors on Friday, October 5th. They now have a $84.42 price target on the stock. Separately, analysts at Independent Research GmbH reiterated a “hold” rating on shares of Sanofi SA in a research note to investors on Thursday, October 4th. They now have a $92.31 price target on the stock. Finally, analysts at CIC Securities reiterated a “hold” rating on shares of Sanofi SA in a research note to investors on Wednesday, October 3rd. They now have a $74.03 price target on the stock.

Shares of Sanofi SA traded down 0.60% during mid-day trading on Wednesday, hitting €66.40. Sanofi SA has a 52 week low of €47.00 and a 52 week high of €69.46. The company has a market cap of €87.499 billion and a P/E ratio of 13.77.

Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.